Intellia Therapeutics Shares Slip Despite Strong Phase 3 Data [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
followed the release of positive Phase 3 results for its hereditary angioedema (HAE) therapy. The data marks the first global Phase 3 outcome for an in vivo gene editing treatment. The company said its Phase 3 HAELO trial evaluating lonvoguran ziclumeran (lonvo-z) achieved its primary endpoint along with all key secondary endpoints. Results showed that a single dose reduced HAE attack rates by 87% compared to placebo over six months, with patients experiencing a mean monthly attack rate of 0.26 versus 2.10 in the placebo group. Trial Results Highlight Durable Efficacy The study included 80 participants, with 52 receiving lonvo-z and 28 assigned to placebo. According to Intellia, most treated patients remained free from both HAE attacks and the need for ongoing therapy throughout the six-month evaluation period. Additionally, all individuals in the treatment group remained off long-term prophylaxis as of the February 10 data cutoff. Regulatory Pathway and Potential Launch Timel
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire
- Intellia Therapeutics (NTLA) had its price target raised by Canaccord Genuity Group Inc. from $48.00 to $58.00. They now have a "buy" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its price target raised by Citizens Jmp from $28.00 to $30.00. They now have a "market outperform" rating on the stock.MarketBeat
- Intellia Therapeutics (NTLA) had its "sell" rating reaffirmed by The Goldman Sachs Group, Inc..MarketBeat
- Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt [Seeking Alpha]Seeking Alpha
NTLA
Earnings
- 2/26/26 - Beat
NTLA
Sec Filings
- 4/27/26 - Form 424B5
- 4/27/26 - Form 8-K
- 4/10/26 - Form 8-K
- NTLA's page on the SEC website